Member Info for AquaeSulis01

It is my daughter with the techie knowledge (ecommerce consultant with 20 yrs experience of online sales), and I did forward the info onto elrico's alter ego, Elric towards the end of Aug for sharing with Stuart, so hopefully now taken onboard

I wish the yoghurt was available in this country, worth sacrificing a few margins and getting it into our supermarkets where the volumes would potentially be huge.

For influencer marketing there are key people who you want to target - dermatologists, holistic medicine advocates and end users - those with skin complaints. Users with circa 10-50k followers are generally most affordable for their reach and tend to give the best value for money. Having several investments in this bracket along with cheaper investments for brand ambassadors with case studies creates the most cost effective way to mass harvest usable content. Tiktok followings tend to be larger than Instagram ones, and the algorithm is more likely to serve posts organically vs insta which really does require paid ads with a decent spend.

- When booking influencers for advertorial, check their engagement rate. It’s no good booking someone with 50k follows with an interaction rate of 0.5% - it’s unlikely their audience will see the content. You can still use these influencers to create content for you, but you’ll need to back it with self-promoted ad spend and host it on your profiles. There’s lots of software you can use to check engagement rates, such as %
https://grin.co/influencer-marketing-tools/engagement-rate-calculator/

Unfortunately, Jennifer's stats read; 69.7K followers, 787 total posts, with a very low engagement rate of 0.19% and Skinbio really do need to pay attention to that latter figure if they want to maximise influencer reach

Thanks for posting mol, first post worth reading today. Let 's hope Beth is one of many new customers being reached as a result of an improvement in the marketing campaign. The product works for most sufferers just need some of those 9.7m American citizens to find out and spread the word

Moab, the Interim Results RNS informs you of the different commercial strategies for US as opposed to other areas;

"ANGLE is encouraged by the interest and discussions are beginning with several leading cancer centres in the United States as well as a UK Government agency. ANGLE is also looking to exploit the FDA clearance and European CE Mark through distributor arrangements in key territories outside the United States and contractual negotiations are in progress."

And what maths and logic are you using to value this growth company with first moving advantage in its field onassis?

Worth a read of the Outlook in the Results RNS to see how many contracts are already in the pipeline with more in the wings post FDA clearance:


"· Pharma services business momentum - discussions in progress with more than twenty biopharma companies offering a pipeline of opportunities for new contracts as we move through the end of this year and into 2023. Almost all potential customers are interested in bespoke assay development



· Global sales and distribution network being established with first contracts in negotiation and initial seeding of instruments anticipated



· Accreditation of clinical laboratories in final stages offering ability to offer validated tests for both pharma services and patient management in coming months



· New product roll-out to accelerate with a pipeline of sample-to-answer imaging and molecular solutions being finalised for offer to customers



· Numerous discussions in progress with potential partners including medtech companies, downstream assay providers and clinical laboratories regarding selected Parsortix based assays



· Continued investment in clinical studies to provide clinical evidence to support long term growth



Garth Selvey, Non-Executive Chairman of ANGLE plc, commented:



"I am delighted that during the period the FDA granted a De Novo Class II classification for the Parsortix system for use in harvesting cancer cells from metastatic breast cancer patient blood for subsequent user-validated analysis. Clearance substantially differentiates ANGLE from the competition and is expected to significantly accelerate commercial adoption of the system in both research and clinical settings.
ANGLE's global pharma services business is gaining traction, with a notable increase in potential customer engagement in the weeks post-FDA clearance and subsequently. We are pleased to see repeat business already coming through from an early major customer and the successful development of our first bespoke assay for another as we start to build our service offering 'menu'.
Demonstration of clinical utility is a key strategic goal for the Company. The positive headline results for the ovarian cancer pelvic mass triage test announced today provide a real world example of the value of molecular analysis of the Parsortix harvest of circulating tumour cells and support the Company's view that this is the "best sample" for analysis for a liquid biopsy."

Personally, agree with Clio, I fall in the somewhere in between camp rather than an extreme.

I suspect that pre-registration interest was indeed very high and no doubt fuelled by a number of traders who got their mates to register an interest in order to drive up company expectations to a point where the initial inventory order was enough to make Skinbiotherapeutics the second highest Customer for Winclove; what other explanation is there and realistically what choice did Stuart have than to place an advance order of that size, so entirely forgivable?
On the downside, Stuart did make the odd error which could have been avoided with a little research, For instance, his podcast statement and belief that the NPF had over 9 million members when that represents the predicted numbers suffering with psoriasis in the US and they certainly are NOT all members (nearer 400K), was a schoolboy mistake and may well of led to him being over optimistic in terms of future sales via this prospective partner.

However, we are where we are, the products are backed by science and work, the concerns I have surround the when substantial revenues arrive not if. For instance, I now view substantial revenue from axisbiotix via a Multi-National deal based on a Pillar negotiation as no longer short term (look at the other pillar negotiations that are still going on years later). So we are looking at Croda VIP's launching this financial year, as predicted by Stuart, to provide the funds to avoid a relatively modest placing to meet Operational plus Research commitments. If it doesn't not the end of the world because will provide substantial funds once launched, but any delay will no doubt cause short term volatility.

Again can't blame Stuart for any external slippage, and if you review Prof Cath's presentation webcast to investors when she was CEO, you will see some very optimistic commercialisation forecasts for dates now in the past.

Which I should add is not surprising if regulars are ordering once every two months at roughly the same time

basic maths lol, just over 50

Thanks Toyin and helpful to know. I can confirm that the order number I was provided with by a friend who is trialling it for arthritis rather than psoriasis order his a week prior to you and was just shy of 3400 so more than 450 orders in a week is heartening to see

In the absence of Toyin providing an answer to axis order numbers, I have sourced it elsewhere and can confirm that circa end September the order numbers had reach circa 3400, so are ticking up nicely. Average monthly sales over 8 months to end Jun we know to be £9000 per month (£72000/8), and I estimate average sales between July-end Sep are approaching twice that now.

POW Investment here looking good.

FIRST CLASS METALS PLC

5th October 2022

High Grade Nickel Sulphide Assays from West Pickle Lake



First Class Metals PLC ("First Class Metals" "FCM" or the "Company") the UK metals exploration company seeking large scale metal discoveries across its extensive Canadian Schreiber-Hemlo & Sunbeam Project land holding is pleased to provide an update on activities in respect to the Pickle Lake Earn In/Joint Venture (JV) ("Pickle Lake JV" "West Pickle Lake") with Palladium One Inc (TSXV:PDM) ("Palladium One").

First Class Metals is delighted to report preliminary assay results form the new West Pickle massive sulphide discovery. The assays from the first hole reported TK-22-059 are of an exceptionally high grade at 4.8% Ni ("Nickel"), 3.7% Cu ("Copper") (6.8% Nickel Equivalent) over 1.8m from Massive Nickle Copper Sulphides, see Table 1



A total of twelve holes have been drilled from which lab assays remain outstanding for eleven holes TK-22-058/TK-22-060 to TK-022-070

Not hundreds and thousands

It hundreds of thousands not motherless Damon kindle

It was around 35 mind in reference Mr Angry. Motherless of thousands but can start to see an uplift. A!so mentioned it put some of t he earlier months to shame. So would you care to to us when you made your last purchase and your order number?

Run it may not have been the exact word but it meant the same. For goodness sake you buy the same stuff and must have noticed your order number has not shot up by thousands since your last purchase

Zoom interview with Elric

Toyin, unless order numbers for axis have suddenly gone through the roof, and Stuart has used the word moderate increases for July/Aug so unlikely to be significant, then skin is where we are looking for any major short term revenue injection, and that is exciting. The fact that Stuart has said there will be no need to raise funds to keep the lights on, having demonstrated what I feel are realistic cash burn figures based on recent RNS's, then Stuart must be anticipating some large returns from early skin ingredient royalties to offset spend.

An early revenue/growth company then. Even using your £2M burn per annum calc and allowing for a modest increase in the £11K per month axis sales, that will be circa £900K burnt by Dec 22 leaving £900K cash in hand which is why the timely launch of skinbiotix which is not in Stuart's gift to control, is so important.

Toyin, the cash burn isn't excessive for an AIM Company but when you do the maths, in the March 2022 half year report to Dec 2021 we had £3.2M cash and all costs for the inventory purchase of £400k axisbiotix and the R&D costs for the Oral Health Care study had been covered in that period. Following the Aug 2022 Trading Update we were informed that cash held at end Jun 2022 was £1.8M, so normal cash burn to cover day-to-day business costs appears to be in the region of £1.4M for 6 mths which is likely to increase as we have appointed a Full Time Finance Director, Marketing Staff and a Non-Exec Director